US-based biopharmaceutical company Trevena has reported positive top-line results from two Phase III clinical trials (APOLLO-1 and APOLLO-2) of oliceridine to treat moderate-to-severe acute pain after bunionectomy and abdominoplasty.

Oliceridine injection is an intravenous (IV) analgesic designed to improve conventional opioid pharmacology to provide the pain-reducing potential of an opioid with minimum associated adverse effects.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The results indicated that all dose regimens met their primary endpoint of statistically greater analgesic efficacy measured by responder rate and showed dose-related trends of improvements on measures of respiratory safety and gastrointestinal tolerability when compared to morphine.

Both the multicentre, randomised, double-blind, placebo-controlled and active-controlled Phase III trials evaluated the efficacy of the injection, but APOLLO-1 involved bunionectomy while APOLLO-2 involved abdominoplasty.

"These successful trials cap a development programme that has shown consistent differentiation of oliceridine from morphine in multiple clinical trials."

Trevena chief executive officer Maxine Gowen said: “We believe the data for all three dose regimens will support the US Food and Drug Administration (FDA) approval of IV oliceridine with a broad indication of management of moderate-to-severe acute pain.

See Also:

"These successful trials cap a development programme that has shown consistent differentiation of oliceridine from morphine in multiple clinical trials."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial's secondary endpoints included comparisons of the injection's efficacy, safety and tolerability to morphine.

A multi-procedure safety Phase III ATHENA trial is also being carried out to evaluate oliceridine in more than 400 patients.

Trevena has received breakthrough therapy designation for oliceridine from the FDA and plans to submit the new drug application (NDA) in the fourth quarter of this year.